ArticleCell death & disease2026
The Sirt2-Nur77 axis regulates muscle stem cell quiescence and senescence via epigenetic-metabolic synergy.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The ageing microenvironment in sarcopenia: early alterations and targeted therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Nur77 expression decreases with age in multiple organs, including the liver, brain, heart, and kidney, whereas Sirt2 increases with age in the mouse cerebral cortex and hippocampus. We identified the central role of the Sirt2-P300/Nur77/K310 acetylation axis in regulating muscle homeostasis and regeneration and its age-related alterations. Consistently, we observed reduced Nur77 and elevated Sirt2 expression in aging skeletal muscle, particularly the anterior tibialis, which is enriched in type IIB and IIA fast-twitch fibers. Mechanistically, Sirt2 promoted Nur77 degradation via K310-specific deacetylation, weakening Myf5 transcriptional activity and altering satellite cell metabolic heterogeneity. Functional tests showed that Sirt2 inhibition (AGK2) or Nur77 activation (CSNB) improved muscle function in aged mice, whereas the K310R mutation led to muscle atrophy and impaired regeneration. These findings suggest the Sirt2-P300/Nur77 axis as a potential therapeutic target for skeletal muscle aging and anti-sarcopenia drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.